Ernexa Therapeutics Inc. share price logo

Ernexa Therapeutics Inc.

NASDAQ: ERNA

Small Cap

$6.20

+0.31

(+5.26%)

as on

Ernexa Therapeutics Inc. Stock Performance

as on June 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $5.62
    $6.19
    downward going graph

    9.35%

    Downside

    -0.16%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.18
    $71.50
    downward going graph

    48.66%

    Downside

    1053.19%

    Upside

    downward going graph

Ernexa Therapeutics Inc. share price movements today

Previous Close
$5.89
Open
$5.99
Volume
172.4K
Day's Low - High
$5.62 - $6.19
52 Week Low - High
$3.18 - $71.50

Ernexa Therapeutics Inc. Historical Returns

1 Month Return
-45.85 %
3 Month Return
-8.15 %
1 Year Return
-90.57 %
3 Year Return
-99.29 %
5 Year Return
0 %

Ernexa Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Ernexa Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.9M

EPS (TTM)

-18.02

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

Industry PE ratio

-3.7464601769911505

PEG Ratio

0

EBITDA

-10.1M

Revenue (TTM)

1.0K

Profit Margin

0.00%

Return On Equity TTM

-2505.61%

Ernexa Therapeutics Inc. Stock Valuation

Track how Ernexa Therapeutics Inc. P/E has moved over time to understand its valuation trends.

Ernexa Therapeutics Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-173.19x)

June 30, 2023

Industry (-3.75x)

June 19, 2026

Today (0.00x)

June 19, 2026

Highest (-0.04x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 0.00x

Ernexa Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Ernexa Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Ernexa Therapeutics Inc. image
Ernexa Therapeutics Inc.
SELL$6.9MNANA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Ernexa Therapeutics Inc. Stock including INR - Dollar returns

The Ernexa Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Ernexa Therapeutics Inc. investment value today

Current value as on today

₹10,272

Returns

-₹89,728

(-89.73%)

Returns from Ernexa Therapeutics Inc. Stock

-₹90,570 (-90.57%)

Dollar Impact

₹842 (+0.84%)

Analyst Recommendation on Ernexa Therapeutics Inc. Stock

Based on 6 analysts

SELL

0.00%

Buy

50.00%

Hold

50.00%

Sell

Based on 6 analysts, 50% of analysts recommend a 'SELL' rating for Ernexa Therapeutics Inc.. Average target price of $30

Ernexa Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Ernexa Therapeutics Inc..

What analysts predicted

79.33%UPSIDE

Target Price

$30

Current Price

$6.2

Analyzed by

6 Analysts

Target

$30.00

Ernexa Therapeutics Inc. target price $30, a slight upside of 79.33% compared to current price of $6.2. According to 6 analysts rating.

Indian Investors' Interest in Ernexa Therapeutics Inc. Stock

Search interest for Ernexa Therapeutics Inc. Stock has decreased by -71% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-71% versus previous 30 day period

Ernexa Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
0
0
0
0
0
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
0
-
0
0
Operating Income
-5
-5
-4
-2
-2
-2
-2
-1
-2
-3
EBITDA
-5
-5
-4
-24
-2
-8
-3
-1
-6
-5
Interest Expense
0
0
0
1
3
0
-
0
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-6
-6
-5
-26
-5
-8
-3
-1
-1
-5
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-6
-6
-5
-26
-5
-8
-3
-1
-1
-5
Net Profit Margin
-36194.12%
-14142.55%
-11763.83%
-5462.83%
-575900.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Ernexa Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
22
21
23
19
5
-
-
0
0
-
Gross Profit
14
14
14
11
0
0
0
0
0
0
Operating Income
-2
-1
0
-1
-7
-113
-33
-21
-15
-9
EBITDA
0
0
3
1
-26
-121
-24
-19
-36
-13
Interest Expense
0
0
0
0
0
0
0
0
6
0
Depreciation
-
-
-
-
0
0
0
0
1
0
Income Before Tax
-2
-1
0
-2
-26
-122
-24
-21
-44
-14
Income Tax Expense
0
0
0
0
-19
0
0
0
0
0
Net Income
-2
-1
0
-2
11
-122
-24
-21
-44
-14
Net Profit Margin
-13.10%
-5.06%
-1.11%
-10.34%
205.28%
0.00%
0.00%
-31864.71%
-7652.75%
0.00%

Ernexa Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-6
-5
-26
-5
-8
-3
-1
-1
-5
Operating Cash Flow
-3
-2
-6
-3
-2
-2
-1
-1
-2
Investing Cash Flow
0
0
0
-
-
-
0
0
0
Financing Cash Flow
1
0
3
1
2
4
0
-7
9
Change in Cash
-2
-2
1
-2
0
2
-1
-1
7

Ernexa Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-1
0
-2
-26
-122
-24
-21
-44
-14
Operating Cash Flow
0
1
2
-8
-23
-20
-20
-15
-7
Investing Cash Flow
-1
-1
-1
0
-22
0
0
0
0
Financing Cash Flow
-1
0
-1
4
61
19
16
6
7
Change in Cash
-2
0
0
-1
15
-1
-3
-9
0

Global Institutional Holdings in Ernexa Therapeutics Inc.

Funds
Holdings
UBS Group AG
0.07%
Bank of America Corp
0%
Sippican Capital Adivsors
0.03%
BlackRock Inc
0%
A. Montag & Associates Inc
0%
See all

Insights on Ernexa Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Ernexa Therapeutics Inc. Common Stock has experienced a drawdown of -99.3%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 77.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.7% return, outperforming this stock by 109.6%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, ERNA stock has moved down by -50.2%

About Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
OrganisationErnexa Therapeutics Inc.
Headquarters1035 Cambridge Street, Cambridge, MA, United States, 02141
IndustryBiotechnology
CEOMr. Sanjeev Luther
E-voting on sharesClick here to vote

Key Management of Ernexa Therapeutics Inc.

Name

Title

Dr. Kanika Chawla Ph.D.

Senior Vice President of Technical Operations (Consultant)

Mr. Sanjeev Luther

CEO, President & Director

Ms. Sandra M. Gurrola

Senior VP of Finance

Dr. Robert Hamilton Pierce M.D.

Chief Scientific Officer

Ms. Dorothy J. Clarke

General Counsel

FAQs

What is Ernexa Therapeutics Inc. share price today?

Ernexa Therapeutics Inc. share price today is $6.2 as on at the close of the market. Ernexa Therapeutics Inc. share today touched a day high of $6.19 and a low of $5.62.

What is the 52 week high and 52 week low for Ernexa Therapeutics Inc. share?

Ernexa Therapeutics Inc. share touched a 52 week high of $71.5 on and a 52 week low of $3.18 on . Ernexa Therapeutics Inc. stock price today i.e. is closed at $6.2,which is 91.33% down from its 52 week high and 94.79% up from its 52 week low.

What is Ernexa Therapeutics Inc.'s market capitalisation today?

Ernexa Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in Ernexa Therapeutics Inc. Stock (ERNA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Ernexa Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ernexa Therapeutics Inc. Shares that will get you 0.2419 shares as per Ernexa Therapeutics Inc. share price of $6.2 per share as on June 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy Ernexa Therapeutics Inc. Stock (ERNA) from India?

Indian investors can start investing in Ernexa Therapeutics Inc. (ERNA) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Ernexa Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Ernexa Therapeutics Inc. share’s latest price of $6.2 as on June 19, 2026 at 8:45 am IST, you will get 1.6129 shares of Ernexa Therapeutics Inc.. Learn more about fractional shares .